The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Update on Extrapulmonary Sarcoidosis

Update on Extrapulmonary Sarcoidosis

December 6, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—Moderated by Dan Mandel, MD, a rheumatologist and associate clinical professor of medicine, the University of California, Irvine, the session Update on Extrapulmonary Sarcoidosis offered participants a multidisciplinary review of the features and management of systemic sarcoidosis.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
  • Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
Also By This Author
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia

Neurology

Dr. Jeffrey Gelfand

Jeffrey M. Gelfand, MD, associate professor of clinical neurology at the University of California, San Francisco, gave the first presentation, which he summarized as “what neurologists want rheumatologists to know about recognizing and treating neurosarcoidosis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He explained that although neurosarcoidosis was traditionally believed to affect approximately 5–10% of all sarcoidosis patients, a more recent series revealed that as many as 15–25% of sarcoidosis patients had evidence of neurosarcoidosis.1 Whatever the actual incidence, Dr. Gelfand emphasized that neurologic involvement increases the risk of morbidity and mortality in patients with sarcoidosis.

“A key clinical teaching point,” said Dr. Gelfand, “is that most—approximately 50–70%, of neurosarcoidosis patients—particularly patients with central nervous system neurosarcoidosis, present with the neurologic syndrome.”1 This neurosarcoidosis presentation then leads to a sarcoidosis diagnosis. According to Dr. Gelfand, in approximately 10–20% of patients, neurosarcoidosis may also occur as isolated to the nervous system. “So although isolated neurosarcoidosis is rare, it’s not that rare,” he emphasized.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In 2018, the Neurosarcoidosis Consortium updated the consensus diagnostic criteria for neurosarcoidosis.2 The bottom line, according to Dr. Gelfand, is that a diagnosis of neurosarcoidosis is made when the clinical presentation and diagnostic evaluation are consistent with neurosarcoidosis with a clinical syndrome typical of granulomatous invasion of the nervous system.

Patients should have pathological evidence of sarcoidosis in the central nervous system or peripheral nervous system for a definite diagnosis. If the patient has pathologic evidence of sarcoidosis elsewhere in their body and a consistent clinical syndrome, they are given a diagnosis of probable neurosarcoidosis.

Absent pathologic confirmation of granulomatous disease, the patient is given a diagnosis of possible neurosarcoidosis. “In many cases probable neurosarcoidosis is as close as we can reasonably get,” said Dr. Gelfand, “for example, in patients with spinal cord or brainstem disease.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In all cases—definite, probable and possible neurosarcoidosis—diagnosis requires rigorous exclusion of other causes, particularly infection and malignancy. “It is this rigorous exclusion of other causes that keeps me up at night as a clinician,” said Dr. Gelfand.

In all cases—definite, probable & possible neurosarcoidosis—diagnosis requires rigorous exclusion of other causes, particularly infection & malignancy.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: ACR Convergence 2021, Fernandez, Gelfand

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
  • Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
  • Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)